問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Thoracic Medicine

Tri-Service General Hospital

Division of General Surgery

Division of Hematology & Oncology

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

Division of Hematology & Oncology

Taipei Medical University Hospital

Division of Hematology & Oncology

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

更新時間：2024-12-10

趙祖怡CHAO, TSU-YI
  • Principal Investigator
  • Clinical Trial Experience (year)

  • 10575@s.tmu.edu.tw

Recruiting Trial

70Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

趙祖怡

List

162Cases

2025-07-07 - 2029-12-31

Phase I

Not yet recruiting
A Phase 1, Open-label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ZE46-0134 in Adults with FLT3 mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

  • Condition/Disease

    FLT3 mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

  • Test Drug

    capsul

Participate Sites
4Sites

Recruiting4Sites

2020-11-20 - 2026-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-09-01 - 2026-04-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2018-01-01 - 2023-12-18

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2019-09-15 - 2027-05-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2025-02-28 - 2032-06-30

Phase III

Active
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)

  • Condition/Disease

    Early breast cancer that is lymph node–positive, estrogen receptor–positive, and human epidermal growth factor receptor 2 (HER2)–negative, with a high risk of recurrence.

  • Test Drug

    Elacestrant

Participate Sites
13Sites

Recruiting13Sites

2024-01-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-09-01 - 2030-06-30

Phase II

Active
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors

  • Condition/Disease

    Advanced/Metastatic Solid Tumors

  • Test Drug

    injection Condensed Powder

Participate Sites
7Sites

Recruiting7Sites

2025-06-06 - 2028-09-13

Phase III

Active
VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer

  • Condition/Disease

    Breast Cancer

  • Test Drug

    Infusion fluid

Participate Sites
7Sites

Recruiting7Sites

2013-01-31 - 2013-12-31

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

1 4 5 6 7 8 17
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB